Steven Seedhouse
Stock Analyst at Raymond James
(3.44)
# 976
Out of 4,996 analysts
178
Total ratings
45.35%
Success rate
5.29%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETNB 89bio | Downgrades: Market Perform | n/a | $14.70 | - | 11 | Sep 19, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $49 | $7.30 | +571.23% | 2 | Sep 17, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $36.71 | +71.62% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $40.66 | +261.53% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $72.76 | +12.70% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.80 | +47.06% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $24.17 | +15.87% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.30 | +669.23% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $7.63 | +162.12% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $25.57 | +306.73% | 20 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $90 → $22 | $1.89 | +1,064.02% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.11 | +563.51% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $112.10 | -17.04% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $28.20 | +141.13% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $22.39 | +373.43% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.54 | +170.76% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $13.15 | +325.86% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.35 | +4,900.00% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $16.31 | +249.48% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $2.41 | +812.86% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.24 | +424.69% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.26 | +973.62% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $56.25 | -32.44% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $42.95 | +65.31% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.70 | +85.19% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $23.58 | +61.15% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $22.17 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.40 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.43 | +2,072.16% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $137.37 | - | 2 | Apr 23, 2020 |
89bio
Sep 19, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $14.70
Upside: -
Astria Therapeutics
Sep 17, 2025
Reiterates: Overweight
Price Target: $49
Current: $7.30
Upside: +571.23%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $36.71
Upside: +71.62%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $40.66
Upside: +261.53%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $72.76
Upside: +12.70%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.80
Upside: +47.06%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $24.17
Upside: +15.87%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.30
Upside: +669.23%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $7.63
Upside: +162.12%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $25.57
Upside: +306.73%
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.89
Upside: +1,064.02%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.11
Upside: +563.51%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $112.10
Upside: -17.04%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $28.20
Upside: +141.13%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $22.39
Upside: +373.43%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.54
Upside: +170.76%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $13.15
Upside: +325.86%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.35
Upside: +4,900.00%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $16.31
Upside: +249.48%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $2.41
Upside: +812.86%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.24
Upside: +424.69%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.26
Upside: +973.62%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $56.25
Upside: -32.44%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $42.95
Upside: +65.31%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.70
Upside: +85.19%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $23.58
Upside: +61.15%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $22.17
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.40
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.43
Upside: +2,072.16%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $137.37
Upside: -